论文部分内容阅读
目的:基于芯片数据库分析的基础上,探讨miR-32在非小细胞肺癌患者中的表达水平。方法:在GEO和Array Expression数据库中搜索关键词“microRNA和肺癌”检索出两个样本量最大的芯片数据,分别是GEO数据库中编码为GSE61741和Array Expression数据库中编码为E-TABM-22的芯片数据,对两组数据进行分析找出有差异的microRNA。另外收集2010.02-2012.09期间在吉林大学附属中日联谊医院胸外科进行肺癌手术切除的32名患者的肺癌组织及配对的癌旁正常肺组织标本,检测标本中miR-32的表达水平。结果:综合分析GSE61741和E-TABM-22的芯片数据发现有共同差异的microRNA共有8个,其中上调的有2个,分别是hsa-miR-192与hsa-miR-197,下调的有6个,分别是hsa-miR-126、hsa-miR-199b-3p、hsa-miR-219-1-3p、hsa-miR-26a、hsa-miR-32与hsa-miR-9。为了进一步探讨miR-32在癌症中的作用,我们对GSE61741中其他癌症患者及健康者血浆中miR-32的芯片数据进行分析,发现miR-32在结肠癌、神经胶质瘤、肾癌、前列腺癌、Wilm’s瘤中的表达水平均显著低于健康者(P<0.01)。对32例及E-TABM-22芯片数据中65例NSCLC患者癌及配对的癌旁正常肺组织中miR-32的表达水平分析发现癌组织中miR-32的表达水平显著下调(P<0.001)。结论:miR-32在非小细胞肺癌组织中低表达,提示miR-32可能为新的NSCLC诊断标记分子。
OBJECTIVE: To investigate the expression of miR-32 in non-small cell lung cancer patients based on on-chip microarray analysis. METHODS: Two key sample data were searched for the key words “microRNA and lung cancer” in the GEO and Array Expression databases, namely the GEO database encoded as GSE61741 and the Array Expression database encoded as E-TABM-22 Of the chip data, the two sets of data analysis to identify differences in microRNA. In addition, 32 lung cancer tissues and paired paracancerous normal lung tissue specimens from 32 patients who underwent lung cancer surgery at the Department of Thoracic Surgery, Sino-Japanese Friendship Hospital affiliated to Jilin University from 2010.02 to 2012.09 were collected to detect the expression of miR-32 in the specimens. Results: Based on the chip data of GSE61741 and E-TABM-22, there were 8 microRNAs with common difference, of which 2 were up-regulated, hsa-miR-192 and hsa-miR- 197, and down-regulated 6 Hsa-miR-199b-3p, hsa-miR-219-1-3p, hsa-miR-26a, hsa-miR-32 and hsa-miR-9 respectively. In order to further explore the role of miR-32 in cancer, we analyzed the microarray data of miR-32 in the plasma of patients with other cancers and healthy individuals in GSE61741 and found that miR-32 is highly expressed in colon, glioma, kidney, prostate The expression of Wilms ’tumor and Wilms’ tumor were significantly lower than those of normal controls (P <0.01). Analysis of miR-32 expression levels in 32 NSCLC patients and 65 paired non-cancerous adjacent normal lung tissues from 32 patients and E-TABM-22 showed that miR-32 expression was significantly down-regulated in cancer tissues (P <0.001) . Conclusion: The low expression of miR-32 in NSCLC suggests that miR-32 may be a new diagnostic marker for NSCLC.